Volume : 11, Issue : 03, March – 2024
Title:
ANALYTICAL METHODS USED FOR ESTIMATION OF ELTROMBOPAG OLAMINE – AN OVERVIEW
Authors :
Sreelatha Gangu*, Gondela Bhagya Laxmi, K Shruthi Laya, Rama Rao Tadikonda, Narender Boggula
Abstract :
Analytical techniques have been developed for the quantitative determination of eltrombopag olamine in bulk and tablet dosage forms. Reverse phase chromatography, liquid chromatography–mass spectrometry, UPLC-MS/MS, HPLC, and RP-UPLC are some of the analytical techniques used for determination of eltrombopag olamine. All the methods produced good results in terms of selectivity and sensitivity. The methods were validated and found to be precise, accurate, and robust. The methods are suitable for pharmaceutical analysis and can be used to study the pharmacokinetics of eltrombopag in humans. The article concluded that the developed methods are useful for the determination of eltrombopag olamine in the pharmaceutical industry for drug development, process validation, and quality control.
Key words: Eltrombopag olamine, RP-UPLC, validation, chronic immune thrombocytopenia.
Cite This Article:
Please cite this article in press Sreelatha Gangu et al., Analytical Methods Used For Estimation Of Eltrombopag Olamine – An Overview., Indo Am. J. P. Sci, 2024; 11 (03).
Number of Downloads : 10
References:
1. Marakatham S, Vallikumari RV, Kumar MS. Spectrophotometric method for determination of eltrombopag in bulk and pharmaceutical formulation. Int J Res Pharm Biosci. 2017; 4:13-16.
2. ICH – Harmonized Tripartite Guideline. Stability testing of new drug substance and products Q1A(R2). International Conference on Harmonization. IFPMA, Geneva, Switzerland, 2003.
3. Basha, D.M. ; G.V. Reddy ; T.S. Rani ; E. Susithra and R. Chekkara. RP-UPLC-MS assay method for eltrombopag: application in pharmaceuticals, human plasma and urine samples. Asian J. Chem. 2015; 27:4615–4619.
4. Zhang Z, Kolesar JM. Eltrombopag: An Thrombopoietin Receptor Agonist for the Treatment of idiopathic Thrombocytopenic Purpura. Clinical Therapeutics. 2011; 33: 1560-1576.
5. Gonzalez JR and Bastida JM. Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Therapeutic Advance in Drug Safety. 2018; 9:263-285.
6. Bauman, J.W. ; C.T. Vincent ; B. Peng ; M.B. Wire ; D.D. Williams and J.W. Park. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J. Clin. Pharmacol. 2011; 51:739-750.
7. Demirhan T, Guksu E, Yazar Y, Keskin E, Atici EB, Özkan SA. Impurity assessment, development and validation of an RP-HPLC method for the determination of eleven potential impurities of eltrombopag precursor. Journal of Pharmaceutical and Biomedical Analysis. 2024; 243:116085.
8. Aabid M, Memon S, Pathan D, Hangad T. Development and validation of a UV spectroscopic method to estimate eltrombopag olamine along with bulk and in-house formulation. Research Journal of Pharmacy and Technology. 2023; 16(11):5010-5014.
9. Jayagopal B, Murugesh S. QBD-driven HPLC method of eltrombopag olamine. Degradation pathway proposal, structure elucidation, and in silico toxicity prediction. Journal of Pharmaceutical and Biomedical Analysis. 2021; 203:114231.
10. Dandabattina R, Subramanian VB, Merugu KS, Sharath Babu H, Katari NK, Kowtharapu LP. Stability-indicating RP-HPLC method development and validation for Eltrombopag Olamine in the presence of impurities and degradation products. Robustness by Design of Expert Software. Journal of AOAC International. 2023; 106(2):267-275.
11. Sreelatha G, RG SC, Harshana T, Spandana YD, Reddy YA. Development And Validation of Visible Spectrophotometric Method for Estimation of Eltrombopag Olamine in Bulk and Tablet Dosage Form. Journal of Advanced Scientific Research. 2023; 14(08):61-65.
12. Mohan TS, Mukkanti K, Jogia HA. Stability Indicating UHPLC Method Development and Validation for Estimation of Eltrombopag and its Related Impurities in Tablet Dosage Form. Oriental journal of chemistry. 2018; 34(2):1098.
13. Maddela R, Gajula R, Pilli NR, Siddiraju S, Maddela S, Makula A. Liquid chromatography–tandem mass spectrometric assay for eltrombopag in 50 μL of human plasma: A pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis. 2014; 98:68-73.
14. Patel AI, Gosai S, Jadav K, Patel AB, Patel NK. Stability indicating analytical method development and validation of eltrombopag olamine in tablet dosage form by RP-UPLC. Journal of the Turkish Chemical Society Section A: Chemistry. 2020; 7(3):845-850.
15. Ali OI, Abd Allah FI, Fahmy EA. Rapid and Sensitive UPLC-MS/MS Validated Method for Eltrombopag Determination in Human Plasma and its Application to Bioequivalence Study. Egypt. J. of Appl. Sci. 2022; 37(11-12):34-48.
16. Ahir K, Patel D, Patel M. Dissolution Method Validation with Reverse Phase Chromatographic Method for Determination of Eltrombopag Drug Release in Dissolution Samples of Tablets. International Journal of Pharmaceutical & Biological Archive. 2020; 11(4):182-189.